Multi-wavelength UV-based PAT tool for measuring protein concentration

Process chromatography is commonly used for purification of therapeutic proteins. Most chromatography skids that are used in such operations utilize single ultraviolet (UV) absorbance for monitoring and quantification of protein content. While the signal from such UV measurement is linear with respect to protein concentration at low values of protein concentrations, as the concentration increases across an eluting product peak, it goes manifold over the linear range, resulting in saturation of the UV signal and as a result incomplete quantification of the protein concentration. This can hamper our ability to decide on where to pool the process chromatography peak. It is evident that a simple, fast, and cost-effective methodology for on-line estimation of protein concentration is the need of the hour. In this paper, a multi-wavelength UV-based approach has been proposed for dilution-free on-line concentration estimation in the range of 0.8-100 g/L. Stable absorbance regions are picked up in the proposed approach from the multi-wavelength UV spectra, thereby offering a solution to the problem of saturation and non-linearity of the UV signal that is otherwise observed at higher concentrations. Further, using chemometrics tools such as principal component analysis (PCA) and partial least squares (PLS), the model has been validated for rapid quantification of protein concentration from the spectra. The predictions from the model were comparable to values measured using an existing UV-based offline method with an R² of>98%. The proposed process analytical technology (PAT) tool was successfully tested online and exhibited<8% variability and could effectively be used from capture to formulation to enable dilution-free online concentration measurement of IgG. The proposed tool is a simple, low-cost alternative to other methods and could enable integrated/continuous operations throughout the downstream train.

Cross-scale quality assessment of a mechanistic cation exchange chromatography model

Cation exchange chromatography (CEX) is an essential part of most monoclonal antibody (mAb) purification platforms. Process characterization and root cause investigation of chromatographic unit operations are performed using scale down models (SDM). SDM chromatography columns typically have the identical bed height as the respective manufacturing-scale, but a significantly reduced inner diameter. While SDMs enable process development demanding less material and time, their comparability to manufacturing-scale can be affected by variability in feed composition, mobile phase and resin properties, or dispersion effects depending on the chromatography system at hand. Mechanistic models can help to close gaps between scales and reduce experimental efforts compared to experimental SDM applications. In this study, a multicomponent steric mass-action (SMA) adsorption model was applied to the scale-up of a CEX polishing step. Based on chromatograms and elution pool data ranging from laboratory- to manufacturing-scale, the proposed modeling workflow enabled early identification of differences between scales, for example, system dispersion effects or ionic capacity variability. A multistage model qualification approach was introduced to measure the model quality and to understand the model's limitations across scales. The experimental SDM and the in silico model were qualified against large-scale data using the identical state of the art equivalence testing procedure. The mechanistic chromatography model avoided limitations of the SDM by capturing effects of bed height, loading density, feed composition, and mobile phase properties. The results demonstrate the applicability of mechanistic chromatography models as a possible alternative to conventional SDM approaches.

Downstream process development strategies for effective bioprocesses: Trends, progress, and combinatorial approaches

The biopharmaceutical industry is at a turning point moving toward a more customized and patient-oriented medicine (precision medicine). Straightforward routines such as the antibody platform process are extended to production processes for a new portfolio of molecules. As a consequence, individual and tailored productions require generic approaches for a fast and dedicated purification process development. In this article, different effective strategies in biopharmaceutical purification process development are reviewed that can analogously be used for the new generation of antibodies. Conventional approaches based on heuristics and high-throughput process development are discussed and compared to modern technologies such as multivariate calibration and mechanistic modeling tools. Such approaches constitute a good foundation for fast and effective process development for new products and processes, but their full potential becomes obvious in a correlated combination. Thus, different combinatorial approaches are presented, which might become future directions in the biopharmaceutical industry.